Selecta Biosciences Inc SELB
We take great care to ensure that the data presented and summarized in this overview for SELECTA BIOSCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SELB
View all-
Artal Group S.A. Luxembourg, N49.14MShares$7.67 Million0.41% of portfolio
-
Black Rock Inc. New York, NY7.25MShares$6.09 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.32MShares$5.3 Million0.0% of portfolio
-
Nano Dimension, Inc.3.79MShares$3.18 Million25.2% of portfolio
-
Geode Capital Management, LLC Boston, MA2.5MShares$2.1 Million0.0% of portfolio
-
State Street Corp Boston, MA2.09MShares$1.75 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY1.43MShares$1.2 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.18MShares$991,2360.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny995KShares$835,4900.0% of portfolio
-
Northern Trust Corp Chicago, IL935KShares$785,7890.0% of portfolio
Latest Institutional Activity in SELB
Top Purchases
Top Sells
About SELB
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Insider Transactions at SELB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 08
2024
|
Michael Singer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
643,630
+49.57%
|
-
|
Apr 08
2024
|
Michael Singer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
110,151
+47.91%
|
-
|
Apr 08
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
826,169
+30.0%
|
-
|
Apr 08
2024
|
Timothy A Springer Director |
SELL
Exercise of conversion of derivative security
|
Indirect |
24,785
-100.0%
|
-
|
Apr 08
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,130,846
+48.54%
|
-
|
Apr 08
2024
|
Timothy A Springer Director |
SELL
Exercise of conversion of derivative security
|
Direct |
123,925
-100.0%
|
-
|
Apr 08
2024
|
Murat Kalayoglu Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,926,764
+49.08%
|
-
|
Apr 08
2024
|
Murat Kalayoglu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
491,853
+49.27%
|
-
|
Apr 08
2024
|
Elizabeth Hoge > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,418,617
+49.17%
|
-
|
Mar 26
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,970,443
+5.63%
|
$1,970,443
$1.46 P/Share
|
Mar 18
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
19,844
+0.41%
|
$0
$0.61 P/Share
|
Mar 15
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
538,700
+1.42%
|
$0
$0.58 P/Share
|
Mar 14
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
650,372
+1.99%
|
$0
$0.54 P/Share
|
Mar 13
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
3,200
+3.08%
|
$0
$0.58 P/Share
|
Mar 12
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
1,200
+1.21%
|
$0
$0.61 P/Share
|
Mar 11
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
1,200
+1.23%
|
$0
$0.65 P/Share
|
Mar 08
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
4,800
+4.8%
|
$0
$0.66 P/Share
|
Feb 07
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
2,400
+2.59%
|
$0
$0.66 P/Share
|
Feb 06
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
800
+0.9%
|
$0
$0.65 P/Share
|
Jan 17
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
800
+0.91%
|
$0
$0.69 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 11.9M shares |
---|---|
Exercise of conversion of derivative security | 11.1M shares |
Open market or private purchase | 1.22M shares |
Other acquisition or disposition | 3.64M shares |
Conversion of derivative security | 3.42M shares |
Sale (or disposition) back to the issuer | 521K shares |
---|---|
Open market or private sale | 3.64K shares |
Exercise of conversion of derivative security | 149K shares |